Last reviewed · How we verify
ABLC
ABLC, marketed by M.D. Anderson Cancer Center, is a targeted therapy that addresses a specific protein or pathway in cancer cells. The drug's key strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ABLC |
|---|---|
| Also known as | Amphotericin B Liquid Complex, Fungizone |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Human Bioequivalence Study of Liposomal Amphotericin B for Injection (NA)
- Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease (PHASE2)
- Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
- Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment (PHASE2)
- Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (PHASE3)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
- A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |